Products Affected - Description
Increlex Injection, Ipsen Pharmaceuticals
10 mg/mL 4 mL vials, package of 10 (NDC 15054-1040-05)
Reason for the Shortage
- Ipsen Pharmaceuticals states the shortage is due to a manufacturing delay and raw material shortage.
- Ipsen is working with FDA to allow the release of Increlex lot #341203F. This lot was produced at an alternate manufacturing site that has not been approved by FDA. Please see the Dear Health Care Provider letter for additional information.
- Additional information is available here and here.
There are insufficient supplies available for usual ordering.
Estimated Resupply Dates
Ipsen has Increlex injection available in limited supply. In order to obtain Increlex, all patients need to go through Ipsen’s patient service and support program, PACE. Further information is available at the link above or by calling 866-435-5677.
July 7, 2014; June 3, 2014; May 19, 2014; May 7, 2014; March 3, 2014; January 6, 2014; October 28, 2013; September 18, 2013, University of Utah, Drug Information Service. Copyright 2014, Drug Information Service, University of Utah, Salt Lake City, UT.
This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins